Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists

James Kim, Blake T. Aftab, Jean Y. Tang, Daniel Kim, Alex H. Lee, Melika Rezaee, Jynho Kim, Baozhi Chen, Emily M. King, Alexandra Borodovsky, Gregory J. Riggins, Ervin H. Epstein, Philip A. Beachy, Charles M. Rudin

Research output: Contribution to journalArticle

204 Citations (Scopus)

Abstract

Recognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act by binding to a common site within Smoothened, a critical pathway component. Acquired Smoothened mutations, including SMOD477G, confer resistance to these inhibitors. Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression. Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMOD477G medulloblastoma.

Original languageEnglish (US)
Pages (from-to)23-34
Number of pages12
JournalCancer Cell
Volume23
Issue number1
DOIs
StatePublished - Jan 14 2013

Fingerprint

Medulloblastoma
Itraconazole
Hedgehogs
Critical Pathways
Basal Cell Carcinoma
Growth
Neoplasms
Mutation
Pharmaceutical Preparations
arsenic trioxide
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists. / Kim, James; Aftab, Blake T.; Tang, Jean Y.; Kim, Daniel; Lee, Alex H.; Rezaee, Melika; Kim, Jynho; Chen, Baozhi; King, Emily M.; Borodovsky, Alexandra; Riggins, Gregory J.; Epstein, Ervin H.; Beachy, Philip A.; Rudin, Charles M.

In: Cancer Cell, Vol. 23, No. 1, 14.01.2013, p. 23-34.

Research output: Contribution to journalArticle

Kim, J, Aftab, BT, Tang, JY, Kim, D, Lee, AH, Rezaee, M, Kim, J, Chen, B, King, EM, Borodovsky, A, Riggins, GJ, Epstein, EH, Beachy, PA & Rudin, CM 2013, 'Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists', Cancer Cell, vol. 23, no. 1, pp. 23-34. https://doi.org/10.1016/j.ccr.2012.11.017
Kim, James ; Aftab, Blake T. ; Tang, Jean Y. ; Kim, Daniel ; Lee, Alex H. ; Rezaee, Melika ; Kim, Jynho ; Chen, Baozhi ; King, Emily M. ; Borodovsky, Alexandra ; Riggins, Gregory J. ; Epstein, Ervin H. ; Beachy, Philip A. ; Rudin, Charles M. / Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists. In: Cancer Cell. 2013 ; Vol. 23, No. 1. pp. 23-34.
@article{d9152d6086b14368977c98ef6087c269,
title = "Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists",
abstract = "Recognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act by binding to a common site within Smoothened, a critical pathway component. Acquired Smoothened mutations, including SMOD477G, confer resistance to these inhibitors. Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression. Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMOD477G medulloblastoma.",
author = "James Kim and Aftab, {Blake T.} and Tang, {Jean Y.} and Daniel Kim and Lee, {Alex H.} and Melika Rezaee and Jynho Kim and Baozhi Chen and King, {Emily M.} and Alexandra Borodovsky and Riggins, {Gregory J.} and Epstein, {Ervin H.} and Beachy, {Philip A.} and Rudin, {Charles M.}",
year = "2013",
month = "1",
day = "14",
doi = "10.1016/j.ccr.2012.11.017",
language = "English (US)",
volume = "23",
pages = "23--34",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists

AU - Kim, James

AU - Aftab, Blake T.

AU - Tang, Jean Y.

AU - Kim, Daniel

AU - Lee, Alex H.

AU - Rezaee, Melika

AU - Kim, Jynho

AU - Chen, Baozhi

AU - King, Emily M.

AU - Borodovsky, Alexandra

AU - Riggins, Gregory J.

AU - Epstein, Ervin H.

AU - Beachy, Philip A.

AU - Rudin, Charles M.

PY - 2013/1/14

Y1 - 2013/1/14

N2 - Recognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act by binding to a common site within Smoothened, a critical pathway component. Acquired Smoothened mutations, including SMOD477G, confer resistance to these inhibitors. Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression. Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMOD477G medulloblastoma.

AB - Recognition of the multiple roles of Hedgehog signaling in cancer has prompted intensive efforts to develop targeted pathway inhibitors. Leading inhibitors in clinical development act by binding to a common site within Smoothened, a critical pathway component. Acquired Smoothened mutations, including SMOD477G, confer resistance to these inhibitors. Here, we report that itraconazole and arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by mechanisms distinct from that of current Smoothened antagonists, retain inhibitory activity in vitro in the context of all reported resistance-conferring Smoothened mutants and GLI2 overexpression. Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMOD477G medulloblastoma.

UR - http://www.scopus.com/inward/record.url?scp=84872417679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872417679&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2012.11.017

DO - 10.1016/j.ccr.2012.11.017

M3 - Article

VL - 23

SP - 23

EP - 34

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -